Bernatowicz Paweł L, Golec Paweł, Bielecki Paweł, Kowal Krzysztof
Department of Haematology, Medical University of Bialystok, Bialystok, Poland.
Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland.
Postepy Dermatol Alergol. 2020 Feb;37(1):61-65. doi: 10.5114/ada.2020.93384. Epub 2020 Mar 9.
The CD163 is exclusively expressed by mononuclear phagocytes as a transmembrane protein, which synthesis is regulated by anti- and pro-inflammatory signals. After shedding from the cell surface it exists in body fluids as a soluble protein (sCD163) which exerts anti-inflammatory effects.
To evaluate serum concentration and production of sCD163 by peripheral blood mononuclear cells (PBMC) in asthmatic patients treated with inhaled (ICS) or oral corticosteroids (OCS).
The study was performed on 35 allergic asthma patients (AAs) including 15 treated with ICS (ICS-AAs), 10 with OCS (OCS-AAs), 10 during asthma exacerbation (EX-AAs) before OCS had been started and 13 non-atopic healthy subjects (HCs) as a control group. PBMC were cultured for up to 144 h. The concentration of sCD163 in serum and the culture supernatants was evaluated with ELISA.
The greatest serum sCD163 concentration was demonstrated in EX-AAs, which was significantly greater than that in other studied subgroups. The concentration of sCD163 in PBMC culture supernatants was greater in AAs than in HCs ( = 0.006). Among individual asthma subgroups the greatest concentration of sCD163 was demonstrated in PBMC culture supernatants of OCS-AAs, which was significantly greater than in ICS-AAs ( < 0.001) and EX-AAs ( < 0.001), both being significantly greater than in HCs ( < 0.001).
In AAs, enhanced capability of PBMCs to release sCD163 may be at least partially responsible for the anti-inflammatory effects of systemic corticosteroid therapy.
CD163作为一种跨膜蛋白，仅由单核吞噬细胞表达，其合成受抗炎和促炎信号调节。从细胞表面脱落之后，它以可溶性蛋白（sCD163）的形式存在于体液中，发挥抗炎作用。
评估吸入性（ICS）或口服糖皮质激素（OCS）治疗的哮喘患者外周血单核细胞（PBMC）中sCD163的血清浓度及产生情况。
该研究对35例过敏性哮喘患者（AA）进行，其中15例接受ICS治疗（ICS-AA），10例接受OCS治疗（OCS-AA），10例在开始使用OCS之前处于哮喘加重期（EX-AA），另有13例非特应性健康受试者（HC）作为对照组。PBMC培养长达144小时。用ELISA法评估血清和培养上清液中sCD163的浓度。
EX-AA组血清sCD163浓度最高，显著高于其他研究亚组。AA组PBMC培养上清液中sCD163浓度高于HC组（P = 0.006）。在各个哮喘亚组中，OCS-AA组PBMC培养上清液中sCD163浓度最高，显著高于ICS-AA组（P < 0.001）和EX-AA组（P < 0.001），后两者均显著高于HC组（P < 0.001）。
在AA患者中，PBMC释放sCD163的能力增强可能至少部分地导致了全身糖皮质激素治疗的抗炎作用。
